-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Compilenewborn
Recently, Gilead announced that the U.
magrolimab, a monoclonal antibody that blocks CD47 signaling, was acquired after Gilead acquired Forty Seven in April 2020 for about $4.
Currently, magrolimab is being developed in several hematological and solid tumor malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML)
In January of this year, the FDA placed a partial clinical hold on multiple clinical studies of magrolimab in combination with azacitidine due to a significant imbalance in investigator-reported suspected unexpected serious adverse reactions (SUSARs) between treatment groups
Clinical studies evaluating magrolimab in combination with azacitidine for the treatment of MDS and AML will now resume patient enrollment in the United States, according to the latest decision issued by the FDA
Gilead is also collaborating with the FDA on the remaining clinical studies of magrolimab in diffuse large B-cell lymphoma (DLBCL) and multiple myeloma (MM) affected by a partial clinical hold
During the partial clinical pause, patients already enrolled in the affected clinical studies of magrolimab, including those in the pivotal Phase 3 ENHANCE study, continued to receive treatment
Reference source: FDA Lifts Partial Clinical Hold on MDS and AML Magrolimab Studies
